Related Experiment Video
Updated: Jul 7, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Cardiac hypertrophy and aortic distensibility in essential hypertension
Insights
Hypertension can cause cardiac hypertrophy by reducing aortic distensibility. Certain blood pressure medications improve arterial stiffness, aiding in the reversal of cardiac hypertrophy.
Area of Science:
- Cardiovascular Medicine
- Hypertension Research
- Vascular Physiology
Background:
- Reduced aortic distensibility and compliance are implicated in cardiac hypertrophy development within hypertensive states.
- In borderline hypertension, altered aortic distensibility shows weak correlation with septal hypertrophy, a marker for cardiac hypertrophy.
- Sustained essential hypertension exhibits a strong correlation between cardiac hypertrophy and increased aortic rigidity.
Purpose of the Study:
- To investigate the relationship between aortic distensibility, arterial stiffness, and cardiac hypertrophy in hypertensive patients.
- To evaluate the impact of different antihypertensive treatments on arterial stiffness and cardiac hypertrophy.
- To understand the role of aortic rigidity modifications in the regression of cardiac hypertrophy.
Main Methods:
- Analysis of aortic distensibility and compliance indices in hypertensive patient cohorts.
- Assessment of septal hypertrophy as a marker for cardiac hypertrophy.
- Comparison of the effects of dihydralazine-like substances, calcium-entry blockers, and converting-enzyme inhibitors on arterial stiffness.
Main Results:
- Aortic distensibility alterations are observed in borderline hypertension but poorly correlate with septal hypertrophy.
- A strong correlation exists between increased aortic rigidity and cardiac hypertrophy in sustained essential hypertension.
- Calcium-entry blockers and converting-enzyme inhibitors improve arterial stiffness, unlike dihydralazine-like substances, at equivalent blood pressure reduction.
Conclusions:
- Aortic rigidity plays a significant role in the development of cardiac hypertrophy in sustained hypertension.
- Improving arterial stiffness through specific antihypertensive medications may be crucial for the regression of cardiac hypertrophy.
- Modifications in aortic rigidity are a key factor to consider when aiming for cardiac hypertrophy reversion in hypertension management.
Abstract:
Reduced aortic distensibility and compliance may participate in the genesis of cardiac hypertrophy in hypertension. In patients with borderline hypertension, indices of aortic distensibility are often altered, but are poorly related to the degree of septal hypertrophy, which is considered to be a marker of cardiac hypertrophy in this particular population. In patients with sustained essential hypertension, the degree of cardiac hypertrophy seems to correlate strongly with the increase in aortic rigidity. Dihydralazinelike substances are unable to modify arterial stiffness, whereas calcium-entry blockers and converting-enzyme inhibitors improve arterial stiffness when achieving the same degree of blood pressure reduction. Modifications in aortic rigidity must be considered in order to understand reversion of cardiac hypertrophy as a result of antihypertensive treatment.
Related Concept Videos
Hypertension and Regulation of Blood Pressure
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertension I: Introduction
Hypertension II: Pathophysiology

